OHR Pharma Offers Positive Interim Top-Line Clinical Data from Phase II Study of Squalamine Eye Drops in Patients with WetAMD
June 24, 2014 at 07:02 AM EDT
Ohr Pharmaceutical, Inc. (Nasdaq: OHRP), an ophthalmology research and development company, today announced positive top-line interim ...